COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
The present disclosure relates generally to methods and compositions for treating symptoms of Parkinson's disease and/or other movement disorders. More particularly, the present disclosure describes a method for treating symptoms of Parkinson's disease and related disorders by administering a composition comprising one or more of the following active agents; estradiol, estriol, testosterone, and 19-nortestosterone. In addition, the compositions of the present invention can be used for enhancing or optimizing the effectiveness of neural stimulation in treating the symptoms of movement disorders such as Parkinson's disease.
1 . A method for treating a patient with Parkinson's disease comprising administering to the patient with Parkinson's disease a composition comprising an active agent, wherein the active agent is selected from one or more of estradiol, estriol, testosterone or 19-nortestosterone.
2 . The method of claim 1 , wherein the composition comprises estradiol and estriol.
3 . The method of claim 1 , wherein the composition comprises estradiol or estriol.
4 . The method of claim 1 , wherein the composition comprises testosterone and 19-nortestosterone.
5 . The method of claim 1 , wherein the composition comprises testosterone or 19-nortestosterone.
6 . The method of claim 1 , wherein the active agent is present in a pharmaceutically acceptable excipient at a concentration of between approximately 10 −9 to about 10 −12 molar.
7 . The method of claim 6 , wherein the active agent is present in at a concentration between 3×10 −9 to 3×10 −10 molar.
8 . The method of claim 1 , wherein the active agent composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.
9 . The method of claim 8 , wherein the composition is administered sublingually.
10 . The method of claim 9 , wherein the composition is administered in a volume between approximately 0.001 ml and 2 ml.
11 . The method of claim 9 , wherein the composition is administered in a volume between approximately 0.05 ml and 1 ml.
12 . The method of claim 9 , wherein the composition is administered in a volume between approximately 0.05 ml and 0.5 ml.
13 . A pharmaceutical composition comprising a solution of approximately 10 −9 to 10 −11 molar of a compound selected from the group consisting of estradiol, estriol, testosterone or 19-nortestosterone for treatment of a movement disorder.
14 . The composition of claim 13 further comprising a pharmaceutically acceptable excipient or carrier.
15 . A method for treating a movement disorder comprising neural stimulation therapy in combination with administration of a signaling solution.
16 . The method of claim 15 , wherein the movement disorder is Parkinson's disease and the signaling solution comprises one or more of estradiol, estriol, testosterone or 19-nortestosterone.
17 . The method of claim 16 , wherein the signaling solution is administered at a concentration of approximately 10 −9 to 10 −11 molar.
18 . The method of claim 15 , wherein the signaling solution is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.
19 . The method of claim 15 , wherein the signaling solution is administered sublingually.
20 . The method of claim 19 , wherein the composition is administered in a volume between approximately 0.001 ml and 2 ml.